Takeda Pharmaceutical (TAK) Cost of Revenue (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Cost of Revenue of $2.6 billion for Q2 2026, down 4.03% year-over-year from $2.7 billion in Q2 2025, and down 1.62% quarter-over-quarter from $2.6 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Cost of Revenue (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Cost of Revenue history runs 10 years deep, the most recent figure standing at $2.6 billion for Q2 2026.
- In Q2 2026, Cost of Revenue fell 4.03% year-over-year to $2.6 billion; the TTM figure through Jun 2026 stood at $15.9 billion (up 1.07% YoY), while the FY2026 annual figure was $10.4 billion, up 0.64% from the prior year.
- Cost of Revenue for Q2 2026 stood at $2.6 billion, down from $2.6 billion in the prior quarter.
- The five-year high for Cost of Revenue was $8.1 billion in Q3 2025, with the low at $2.2 billion in Q3 2022.
- The 5-year median for Cost of Revenue is $2.5 billion (2025), against an average of $3.4 billion.
- The sharpest annual moves came in 2022 and 2023: Cost of Revenue fell 11.72% in 2022, then soared 226.94% in 2023.
- Takeda Pharmaceutical's Cost of Revenue stood at $2.4 billion in 2022, then grew by 8.81% to $2.6 billion in 2023, then dropped by 2.77% to $2.5 billion in 2024, then increased by 4.78% to $2.6 billion in 2025, then fell by 3.21% to $2.6 billion in 2026.
- Business Quant data shows TAK's Cost of Revenue at $2.6 billion in Q2 2026, $2.6 billion in Q1 2026, and $2.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 98.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.55 Bn |
| Jun 30, 2026 | 2.55 Bn |
| Mar 31, 2026 | 2.59 Bn |
| Mar 31, 2026 | 2.59 Bn |
| Dec 31, 2025 | 2.64 Bn |
| Dec 31, 2025 | 2.64 Bn |
| Sep 30, 2025 | 8.13 Bn |
| Sep 30, 2025 | 8.13 Bn |
| Jun 30, 2025 | 2.66 Bn |
| Jun 30, 2025 | 2.66 Bn |
| Mar 31, 2025 | 2.54 Bn |
| Mar 31, 2025 | 2.54 Bn |
| Dec 31, 2024 | 2.52 Bn |
| Dec 31, 2024 | 2.52 Bn |
| Sep 30, 2024 | 8.03 Bn |
| Sep 30, 2024 | 8.03 Bn |
| Jun 30, 2024 | 2.49 Bn |
| Jun 30, 2024 | 2.49 Bn |
| Mar 31, 2024 | 2.61 Bn |
| Mar 31, 2024 | 2.61 Bn |